Checkpoint Inhibitors for Treating Cancer Market Report 2018-2028 - Visiongain Report

LONDON, May 1, 2018 /PRNewswire/ --

Analysing Prospects for PD-1 Inhibitors, CLTA-4 Inhibitors and Pipeline Drugs

Report Details 

Checkpoint Inhibitors for Treating Cancer - our new study reveals trends, R&D progress, and predicted revenues
Where is the Checkpoint Inhibitors for Treating Cancer market heading? If you are involved in this sector you must read this newly updated report. Visiongain's report shows you the potential revenues streams to 2028, assessing data, trends, opportunities and business prospects there.

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

Discover How to Stay Ahead
Our 161-page report provides 107 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Checkpoint Inhibitors for Treating Cancer market. See how to exploit the opportunities.

Forecasts to 2028 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2028, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, there are forecasts for 3 submarkets and 5 Drugs in the report at a global level, as well as profiles for 14 pipeline drug candidates

Global Checkpoint Inhibitors for Treating Cancer Market by Type
• PD-1 Inhibitors
• CLTA-4 Inhibitors
• Pipeline Drugs

Global Checkpoint Inhibitors for Treating Cancer Market by Drug
• Opdivo (nivolumab)
• Keytruda (pembrolizumab)
• Yervoy (ipilimumab)
• Tecentriq (Atezolizumab)
• Tremelimumab (CP-675,206) 

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 8 major regional/national markets:
• The US
• Japan
• Germany
• The UK
• Italy
• France
• Spain
• Asia-Pacific

The report also includes profiles and for some of the leading companies in the Checkpoint Inhibitors for Treating Cancer market, with a focus on this segment of these companies' operations.

There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, the US, the UK and the APAC region in particular, will continue to achieve high revenue growth to 2028.

Leading companies and the potential for market growth
Overall world revenue for Checkpoint Inhibitors for Treating Cancer will surpass $7.9bn in 2018, our work calculates. We predict strong revenue growth through to 2027.

Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Checkpoint Inhibitors for Treating Cancer Market report helps you
In summary, our 161-page report provides you with the following knowledge:
• Revenue forecasts to 2027 for the Checkpoint Inhibitors for Treating Cancer market, with forecasts for 3 submarkets and 5 Drugs, each forecasted at a global level - discover the industry's prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2028 for 8 key regional and national markets - See forecasts for the Checkpoint Inhibitors for Treating Cancer in Asia-Pacific, the US, Germany, France, the UK, Italy, France, and Japan,
• What stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market - including company profiles for some of the major companies involved in the Checkpoint Inhibitors for Treating Cancer market

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our newly updated report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.

Visiongain's study is for everybody needing commercial analyses for the Checkpoint Inhibitors for Treating Cancer market and leading companies. You will find data, trends and predictions.

Get our report today Checkpoint Inhibitors for Treating Cancer Market Report 2018-2028: Analysing Prospects for PD-1 Inhibitors, CLTA-4 Inhibitors and Pipeline Drugs.

To request a report overview of this report please email Sara Peerun at sara.peerun@visiongain.com or call Tel: +44 (0) 20 7336 6100

Or click on: https://www.visiongain.com/Report/2177/Checkpoint-Inhibitors-for-Treating-Cancer-Market-Report-2018-2028

Companies Mentioned in the Report 

Aurigene

4-Antibody AG

Abbott

AbbVie

Adimab

Advaxis

Agenus

AgonOX

Ambrx

Amgen

Amplimmune

AnaptysBio

arGEN-X

Bayer

BeiGene

Bio-Matrix Scientific Group

BioWa

Boehringer Ingelheim

Bristol Myers Squibb

Celgene

Cell Genesys 

Celldex Therapeutics

Compugen

CoStim Pharmaceuticals

CureTech

Eddingpharm

Facet Biotech

Five Prime Therapeutics

Gilead BioSciences

GITR /Tolerx

GlaxoSmithKline

HealthCare Ventures

IDM

Immutep

Incyte Corporation

Innate Pharma

iTeos Therapeutics

KAHR Medical

Kyowa Hakko Kirin

Laureate Pharma

Lee's Pharma 

Lonza Biologics

MacroGenics 

Medarex

MedImmune/AstraZeneca

Medivation

Merck

Merck Serono

Millennium Pharmaceuticals

MolMed S.p.A

MorphoSys

MRC Technology

NewLink Genetics

Novartis

Novo Nordisk

Oncothyreon

Ono Pharmaceutical

Onyx (subsidiary of Amgen) 

Orega Biotech

PDL Biopharma

Pfizer

Pierre Fabre

Prima BioMed 

Recipharm Cobra Biologics

Regis Technologies 

Roche/Genentech

Samsung Biologics

Seattle Genetics

Servier

Sorrento Therapeutics

Spring Bioscience

Tesaro

ToleroTech

Ventana Medical Systems

To see a report overview please email Sara Peerun on sara.peerun@visiongain.com